title: [STI 571 for treating 19 patients with chronic-phase chronic myeloid leukemia].
abstract: OBJECTIVE
  To compare the therapeutic effects of STI 571 in treating Philadelphia chromosome (Ph)-positive patients with chronic-phase and acceleration phase chronic myeloid leukemia (CML-CP and CML-AP, respectively).
  
  
  METHODS
  A total of 19 CML patients with Ph chromosome and/or fluorescence in situ hybridization (FISH)-bcr/abl fusion gene positivity rates over 90% and a median age of 38 years were recruited in this study, 12 of whom had previously failed to respond to interferon-alpha. Five of the 19 patients were in accelerated phase and 14 in chronic phase, 9 of the latter patient group in early stage of CML-CP (within 1 year since diagnosis) and 5 in advanced stage (3-6 years since diagnosis). All the patients were given oral STI 571 at the dose of 300-500 mg/d for a median treatment course of 5 months, and the 5 patients with CML-AP also received homoharringtonine at dose of 1-2 mg/d for an average of 1.5 treatment cycles (7-14 d for a complete treatment cycle). The Ph chromosome and the FISH-bcr/abl were analysed again 3 months after the treatment.
  
  
  RESULTS
  STI 571 induced 100% complete hematological remission (CHR) and 79% major cytogenetic responses (MCR) in these patients. The complete cytogenetic remission (CCR) rates of CML-AP patients and CML-CP patients in advanced stage were lower than that of CML- CP patients in early stage (0% and 40% vs 88.9%).
  
  
  CONCLUSIONS
  STI 571 can achieve high rate of CHR and MCR in CML-CP patients, especially in those in early stage of the disease.
authors: Department of Hematology, Nanfang Hospital, First Military Medical University, Guangzhou 510515, China. mengfu@medmail.com.cn
authors: Fan-yi
authors: FY
authors: Meng
authors: Wei-yang
authors: WY
authors: Zheng
authors: Xiao-li
authors: XL
authors: Liu
authors: Bing
authors: B
authors: Xu
authors: Lan-lin
authors: LL
authors: Song
authors: Yu
authors: Y
authors: Zhang
authors: Fen
authors: F
authors: Huang
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D015466:Leukemia, Myeloid, Chronic-Phase / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate